Last updated on December 2018

A Phase 3 Randomized Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Brief description of study

The study seeks to evaluate the efficacy and tolerability of veliparib/placebo in combination with carboplatin and paclitaxel in HER2-negative metastatic or locally advanced, unresectable, BRCA-associated breast cancer.

Clinical Study Identifier: NCT02163694

Contact Investigators or Research Sites near you

Start Over

Abbvie Emerging Med

Azienda Ospedaliera Bianchi Melacrino Morelli /ID# 125263
Reggio Calabria, Italy